Carl Zeiss Meditec AG ADR (CZMWY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Carl Zeiss Meditec AG ADR (CZMWY) is down 34.0% since the beginning of the year. At $30 per share, CZMWY is trading 58.3% below its 52-week high of $73. Investors who bought $1,000 worth of CZMWY shares 5 years ago would now be looking at an investment worth $178.

Carl Zeiss Meditec AG ADR (CZMWY) has returned -33.98% so far this year and -49.94% over the past 12 months. Over the last ten years, CZMWY has returned -1.23% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Mar 30, 2009, CZMWY's average daily return is +0.04%, while the average monthly return is +0.91%. At this rate, an investment would double in approximately 6.4 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jan 2025 with a return of +30.1%, while the worst month was Jan 2026 at -29.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, CZMWY closed higher 23% of trading days. The best single day was May 7, 2012 with a return of +16.9%, while the worst single day was Jun 17, 2024 at -18.9%.

Carl Zeiss Meditec AG ADR has an annualized alpha of 4.43%, beta of 0.46, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 31, 2009.

• This stock participated in 86.79% of S&P 500 Index downside but only 61.37% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.46 may look defensive, but with R2 of 0.06 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CZMWY ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Carl Zeiss Meditec AG ADR (CZMWY) and compare them to S&P 500 Index.

Carl Zeiss Meditec AG ADR provided a 2.08% dividend yield over the last twelve months, with an annual payout of $0.63 per share.

The table displays the monthly dividend distributions for Carl Zeiss Meditec AG ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Carl Zeiss Meditec AG ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Carl Zeiss Meditec AG ADR was 88.28%, occurring on Mar 18, 2026. The portfolio has not yet recovered.

The current Carl Zeiss Meditec AG ADR drawdown is 86.43%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Carl Zeiss Meditec AG ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Carl Zeiss Meditec AG ADR is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.